Travere Set For Big Expansion As Filspari Wins Full Approval In IgAN
Company Hopes To Soften REMS
Executive Summary
The drug maker could end up doubling the addressable patient population for Filspari thanks to the new label removing the proteinuria threshold, plus a draft treatment guideline from a kidney disease group.